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Abstract: Caffeine use is increasing worldwide. The underlying motivations are mainly concentration and 
memory enhancement and physical performance improvement. Coffee and caffeine-containing products affect 
the cardiovascular system, with their positive inotropic and chronotropic effects, and the central nervous 
system, with their locomotor activity stimulation and anxiogenic-like effects. Thus, it is of interest to examine 
whether these effects could be detrimental for health. Furthermore, caffeine abuse and dependence are becoming more and 
more common and can lead to caffeine intoxication, which puts individuals at risk for premature and unnatural death. The 
present review summarizes the main findings concerning caffeine’s mechanisms of action (focusing on adenosine 
antagonism, intracellular calcium mobilization, and phosphodiesterases inhibition), use, abuse, dependence, intoxication, 
and lethal effects. It also suggests that the concepts of toxic and lethal doses are relative, since doses below the toxic 
and/or lethal range may play a causal role in intoxication or death. This could be due to caffeine’s interaction with other 
substances or to the individuals' pre-existing metabolism alterations or diseases.  
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INTRODUCTION 
 The use of caffeine to stay awake and alert is a long-
standing habit. Coffee is the most popular beverage after 
water and is consumed worldwide in daily amounts of 
approximately 1.6 billion cups, which is quite an impressive 
figure.  
 There is some uncertainty about the etymology of the 
word “coffee”. The botanical name of the plant from which 
coffee is derived is Coffea Arabica: it finds its origins in 
Ethiopia and is an exceptionally hardy self-pollinating plant. 
The Persian physician Rhazes was the first to mention it in 
his manuscripts. Yemen was the first country to cultivate the 
coffee plants, whilst Turkey was the first country to roast the 
green coffee beans. So it is not surprising that the word 
“coffee” finds its roots in Arabia, where it was called 
“qahwah”. Although there is no doubt about the origin of the 
word, researchers do not agree on how the language process 
led the English word “coffee”. It is likely that the latter 
found its way into European languages in the 17th century 
from the Italian word “caffé”, stemming, in turn, from the 
word “kahveh”, which was the Turkish way to pronounce 
“qahwah”. Over the centuries, the habit of drinking coffee 
spread from Arabia to all the world.  
 Caffeine is contained in more than sixty plants, which is 
a remarkable number, thus it has been hypothesized that  
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caffeine was originally a minor nutrient, not essential for the 
plant, but extremely useful as a pesticide. In fact, caffeine is 
toxic for several insects and animals, especially herbivores. 
Through caffeine the plant may defend itself and have a 
better chance of survival: in this view, caffeine can be 
considered as a “co-evolutionary protecting agent” [1]. 
 “The Canon of Medicine”, written in 1025 by the Persian 
physician Avicenna, is the first text mentioning coffee as a 
medication. At the time, coffee was used to “clean the skin, 
dry up the humidities that are under it, and give a better odor 
to the body”. In the 15th century, the diffusion of coffee, 
initially employed by Muslim dervishes for providing 
energy, had remarkably increased and countless coffee 
houses had opened in Arabia. In the late 17th and in the 18th 
century, as sea shipping had expanded, the use of coffee 
became common in Europe [2].  
 The stimulant effects of caffeine on the central nervous 
system have been known for centuries [3]. In the 19th century 
a well-known consumer was Honoré De Balzac. Saying that 
he loved the coffee is not enough. He was completely 
dependent on it and in the period in which he wrote “The 
Human Comedy” he went on to drink up to 50 cups a day. In 
1830, he published an article in a French magazine called 
“Pleasures and pains of coffee”, which recounted: "coffee 
slips into the stomach and you immediately feel a general 
commotion. Ideas begin to move like the battalions of the 
Grand Army on the field of the battle and the battle takes 
place. Memories come at a gallop, carried by the wind”. 
Nowadays, caffeine is believed to be the most frequently 
consumed psychostimulant worldwide, being ingested 
predominantly as coffee. Many other caffeine-containing 
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beverages and products exist and contain significant amounts 
of the substance, for example, tea, chocolate, cocoa 
beverages, soft drinks, and energy drinks. Coffee and 
caffeinated beverages are part of the diet in all countries. 
 With regard to cognitive functions, caffeine’s properties 
have been investigated in both human and animal studies. In 
epidemiological reports, a link between chronic caffeine 
consumption and a significantly lower risk of developing 
neurodegenerative diseases, such as Alzheimer’s disease, has 
been described [4]. Likewise, chronic treatment with caffeine 
has been shown to be effective in preventing β-amyloid (Aβ) 
production and memory deficits in experimental models of 
Alzheimer’s disease [5, 6]. While caffeine seems to prevent 
or restore memory impairment due to disturbances in brain 
homeostasis [7], its cognition-enhancing properties are still a 
matter of debate [8, 9]. Besides, moderate-to-high consumers 
develop tolerance to caffeine and only low or nonconsumers 
can eventually benefit from an acute administration [10]. 
 In addition, in epidemiological reports [11] and 
experimental models [12, 13], caffeine has been found to 
have a role in the prevention of motor symptoms and loss of 
dopaminergic neurons in Parkinson’s disease. 
 With regard to physical activity, it should be noted that 
until 2004 the International Olympic Committee listed 
caffeine in its prohibited substances list. Professional athletes 
who tested positive for more than 12 µg/l of urine – which 
corresponds to drinking about 5-6 cups of coffee in a day – 
were banned from the Olympic games [14]. 
 In the past years, a relationship between coffee 
consumption and several types of cancers, such as colon, 
bladder, and pancreatic ones, has been postulated. Yet, the 
recent literature has provided no evidence of this relationship 
[15, 16]. 
METHODS 
Eligibility Criteria 
 The present conceptual review was performed by 
including retrospective, prospective, and transversal (i.e., 
cross-sectional) studies examining caffeine’s mechanisms of 
action, use, abuse, dependence, and intoxication, which may 
lead to death. 
Search Criteria and Critical Appraisal  
 As regards the search strategy, an electronic search of 
Pubmed, INFORMA healthcare, Excerpta Medica Database 
(EMBASE), and PsycINFO from the inception of these 
databases to July 20, 2014 was performed. The search 
included publications in any language. Search terms were 
caffeine AND “pharmacokinetics” OR “pharmacodynamics” 
OR “heart” OR “brain” OR “abuse” OR “dependence” OR 
“intoxication” OR “death” in title, abstract, and key-words. 
Reference lists of all located articles were further searched 
for the detection of still unidentified literature and its 
evaluation. 
Search Results and Included Studies  
 From each electronic database, we read all titles and 
selected those promising ones to be relevant, which were 
29,421. Through a hand search of reference lists 20 other 
potentially eligible articles were singled out.  
Risk of Bias 
 No evidence of language bias was found, as the search 
was not limited to English language studies. This limited the 
possibility of missing relevant studies. Moreover, no proof of 
significant publication bias was found. The database search 
produced no unpublished study, initiating, ongoing, or 
finished. 
RESULTS 
Pharmacokinetics and Pharmacodynamics  
 After ingestion, caffeine is quickly absorbed from the 
gastrointestinal tract into the circulatory system [17, 18]. The 
maximum plasma concentration is reached after 30-60 
minutes from consumption. However, maximum plasma 
concentrations reached between 15 and 120 min have been 
reported, due to inter-individual differences and delayed 
gastric emptying. Caffeine is widely distributed through the 
body. The pre-systemic (i.e., first-pass) metabolism takes 
place in the liver, since orally ingested substances are 
absorbed through the small intestine into the portal 
circulation, before entering the systemic one. Caffeine’s pre-
systemic metabolism is negligible [17] and, once caffeine is 
absorbed, it promptly gets into all the body tissues and 
crosses the blood-brain, blood-placenta, and blood-testis 
barriers [17, 19]. The hepatic microsomal enzyme system is 
in charge of caffeine metabolism in the liver. The main 
enzyme responsible for caffeine metabolism is cytochrome 
P450 1A2 (CYP1A2), which accounts for about 95% of 
caffeine clearance. Caffeine metabolism rate is controlled 
not only by CYP1A2, but also by xanthine oxidase and N-
acetyltransferase 2 (NAT2) [20]. Only from 0.5% to 2% of 
ingested caffeine is excreted as such in the urine, as it 
undergoes an almost complete tubular reabsorption [17]. 
Caffeine’s half-life in humans ranges from a minimum of 2 
to a maximum of 12 hours [21, 22], mainly due to the inter-
individual variability in absorption and metabolism. When 
levels of intake are higher, a prolonged duration of action 
can be observed, possibly because of a delay in caffeine 
clearance and an accumulation of paraxanthine and other 
xanthines. In fact, caffeine is subjected to demethylation, 
resulting mostly in the release of paraxanthine (84%), 
followed by theobromine (12%) and theophylline (4%). The 
chemical structure of the xanthines theobromine and 
theophylline is very similar to that of caffeine [23]. These 
metabolites are further transformed in the liver through 
demethylation and oxidation, resulting in the production of 
urates [24].  
 Paraxanthine, the key metabolite of caffeine, has a 
similar chemical structure and half-life to those of caffeine 
and is easily measured in serum and urine. About 60% of 
orally ingested paraxanthine is excreted unmodified. 
Compared to caffeine, paraxanthine’s production and 
degradation rates are similar, but serum concentration is 
more stable throughout the day, even if it reflects only recent 
consumption [25]. Paraxanthine’s plasma levels decrease 
more slowly, even after accounting for inter-individual 
metabolism variations, and they become higher after 8-10 
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hours from ingestion [17]. Paraxanthine is then metabolized 
through two alternative pathways: the former produces  
8-hydroxyparaxanthine, the latter, consisting in the  
7-demethylation of paraxanthine, produces three metabolites, 
i.e., 5-acetylamino-6-formylamino-3-methyluracil (AFMU), 
1-methylxanthine, and 1-methylurate [26]. AFMU makes up 
for 67% of paraxanthine metabolites [17] and is converted to 
5-acetyl-6-amino-3-methyluracil (AAMU), which can be 
measured in the urine without any difficulty. The paraxanthine 
metabolites are excreted in the urine almost as rapidly as 
they are produced, as a result of an active renal tubular 
secretion [26]. Because of the high caffeine doses and the 
repeated consumption of coffee that are typical of the daily 
caffeine consumer, paraxanthine accumulates in the plasma 
and this process reduces caffeine elimination. Paraxanthine, 
as mentioned above, has many similar effects to those of 
caffeine and, consequently, daily caffeine consumption 
generates high levels of both caffeine and paraxanthine, 
which are biologically active.  
 Theobromine constitutes the higher proportion of the 
biologically active metabolites [27]. It is rapidly absorbed 
and about 50% is excreted through the urine in 8-12 hours 
[28]. Its effects include diuresis induction, cardiovascular 
system stimulation, smooth muscle relaxation, and glandular 
secretion [29]. CYP1A2 and, to a smaller extent, CYP2E1, 
are responsible for theobromine’s metabolism, as they 
determine 86% of its demethylation [30]. Theobromine’s 
half-life is approximately 7-11 hours [28, 31] and plasma 
and renal clearance are about 46% and 67%, respectively 
[32]. Plasma clearance is influenced by smoking: smokers 
show a 30% higher clearance than nonsmokers [33]. 
 Theophylline and caffeine share a similar chemical 
structure, however theophylline lacks one N-methyl group 
and determines more potent effects than caffeine and 
theobromine. Its half-life is quite unpredictable, varying 
from 3 to 9 hours [34]. Theophylline is subjected to hepatic 
and renal clearance. Hepatic clearance is mediated essentially 
by CYP1A2, via an N-demethylation that leads to the 
production of monomethylxanthines and an 8-hydroxylation 
that leads to the production of 1,3-dimethyl-uric acid. 
 In conclusion, there are significant inter-individual 
differences in the metabolism, clearance, and elimination of 
caffeine and its metabolites. Several extrinsic factors 
influence metabolic and excretion rates, such as smoking, 
food intake, gastric emptying speed, pregnancy, hepatic and 
cardiovascular diseases, viral infections, and concomitant 
drug use.  
 In particular, smokers are characterized by a metabolism 
rate that is almost twice the one of nonsmokers [35]. 
Cigarettes contain polycyclic aromatic hydrocarbons that 
promote a greater liver enzyme activity, thereby increasing 
caffeine metabolism [26, 36]. Smoking may accelerate the 
pre-systemic (i.e., first-pass) and systemic (i.e., second-pass) 
metabolism of caffeine, with the hepatic microsomal 
oxidative enzymes causing a faster demethylation [37, 38]. 
 Pregnancy decreases the clearance and excretion of 
caffeine, thus the latter and its metabolites, such as 
theophylline, can accumulate in the body [34]. Variations in 
enzyme activity, especially with regard to CYP1A2, are 
reported. As a result, there is a growing effort to identify 
genetic polymorphisms influencing caffeine metabolism  
[26, 39].  
Mechanisms of Action 
 The potential effects of caffeine, at the cellular level, can 
be explained by three mechanisms of action: the antagonism 
of adenosine receptors, especially in the central nervous 
system; the mobilization of intracellular calcium storage; the 
inhibition of phosphodiesterases. 
Antagonism of Adenosine 
 Caffeine blocks adenosine receptors, mainly A1 and A2A 
subtypes, competitively antagonizing their action [40, 41] 
and causing an increased release of dopamine, noradrenalin, 
and glutamate [42, 43]. Caffeine is able to reduce cerebral 
blood flow [44]. It is also able to reduce myocardial blood 
flow, by inhibiting A1, A2A and A2B adenosine receptors in 
blood vessels and limiting adenosine-mediated vasodilation 
[45]. A1 receptors can be found in almost all brain areas. The 
highest concentration is in the cerebral and cerebellar 
cortices, the hippocampus, and a number of thalamic nuclei 
[46, 47], whereas only a modest concentration is found in the 
corpus striatum, i.e. the caudate and putamen, and the 
nucleus accumbens. Pre-synaptic A1 receptors inhibiting the 
release of neurotransmitters are present in almost all types of 
neurons.  
 There is significant evidence of a relationship between 
adenosine A2A and dopamine D1 receptors [42]. Adenosine 
A2A and D2 receptors show a high concentration in the 
dopamine-rich areas of the brain, i.e., the corpus striatum, 
the nucleus accumbens, and the tuberculum olfactorium, 
where they are co-localized. There is little evidence 
supporting their presence outside these areas, even if, 
according to recent functional neuroimaging studies, they 
may be present in the cerebral cortex and the hippocampus. 
The blockade of A2A receptors in the basal ganglia, i.e., the 
corpus striatum and globus pallidus, appears to be fundamental 
for the stimulatory effects of caffeine [48]. These effects 
largely depend on an intact dopaminergic neurotransmission. 
Finally, it has been shown that the effects of caffeine in low 
doses can be replicated by a selective A2A receptor antagonist, 
but not by a selective A1 receptor antagonist [49]. These 
findings suggest that the interaction between caffeine in  
high doses and dopaminergic transmission finds its roots  
in the increase of post-synaptic D2 receptor transmission. 
The antagonistic effects of caffeine on the A2A adenosine 
receptors in the corpus striatum are in line with the  
reduced risk of developing Parkinson’s disease when 
caffeine consumption is increased [9]. 
 The ability of caffeine to block adenosine receptors can 
be observed also at low doses, such as those contained in a 
single cup of coffee.  
 Other mechanisms of action, such as the mobilization of 
intracellular calcium and the inhibition of phosphodiesterases, 
require higher doses of caffeine, unlikely to be obtained with 
the common daily dietary sources of caffeine. 
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Mobilization of Intracellular Calcium 
 Caffeine can induce calcium release from the 
sarcoplasmic reticulum [50] and can also inhibit its reuptake 
[51]. Through these mechanisms, caffeine can increase 
contractility during submaximal contractions in habitual and 
nonhabitual caffeine users. Intracellular calcium determines 
the activation of endothelial nitric oxide synthase (eNOS), 
with the production of higher quantities of nitric oxide [47]. 
Therefore, some of the effects induced by caffeine might be 
partly mediated by neuromuscular function modulation and 
contractile force increase in the skeletal muscles [52, 53]. 
 A potential counter effect of caffeine is represented by 
diuresis stimulation, accountable for ergolytic effects in 
endurance athletes during prolonged workouts and competitions 
[54].  
Inhibition of Phosphodiesterases 
 Caffeine acts as a nonselective competitive inhibitor of 
phosphodiesterases [55]. These enzymes hydrolyze the 
phosphodiester linkages in molecules, such as cyclic adenosine 
monophosphate (cAMP), inhibiting their degradation. cAMP 
stimulates lipolysis by triggering the activity of the hormone-
sensitive lipase (HSL) and has a vital role in the adrenaline 
cascade [56]. It also activates protein kinase A, which in turn 
phosphorylates several enzymes implicated in glucose and 
lipid metabolism [57]. These mechanisms of action require 
very high doses of caffeine, unlikely to be present in the 
standard diet, which contains moderate amounts of caffeine. 
 Further mechanisms of action describe the use of caffeine 
in sport activities and as a dietary supplement that are 
described below. 
Increase of Post-exercise Muscle Glycogen Accumulation 
 Faster recovery following intense exercise, mediated by a 
higher rate of glycogen resynthesis, has been described [58]. 
It has been maintained that caffeine ingestion has no effect 
on glycogen stacking during recovery from exercise in 
recreational athletes [59]. However, a recent study has found 
that caffeine (8 mg/kg body weight), coingested with 
carbohydrates, is responsible for higher rates of post-exercise 
muscle glycogen stacking in comparison to the ingestion of 
carbohydrates alone in well-trained athletes after the 
depletion of glycogen that follows exercise [60]. Although 
this finding deserves further investigation in broader 
population samples (recreational and professional athletes, 
untrained individuals) and occasions (during exercise or 
recovery), caffeine in addition to post-exercise carbohydrates 
consumption seems to be able to stimulate glycogen 
resynthesis. 
Increase of Fatty Acid Oxidation 
The increase of lipolysis determines a decreased dependence 
from glycogen use [61]. Caffeine switches the substrate 
preference from glycogen to lipids by stimulating HSL 
activity and inhibiting glycogen phosphorylase activity [62]. 
Effects on the Cardiovascular System 
 Caffeine has several effects on the cardiovascular system, 
which have been examined thoroughly with conflicting 
result. Many mechanisms have been suggested in relation to 
caffeine toxicity, which primarily affects the cardiovascular 
system.  
 In the heart, adenosine acts through specific receptors 
and is a negative inotropic and chronotropic agent. The 
blockade of cardiac adenosine receptors inhibits adenosine’s 
effects and can cause tachycardia and arrhythmias through 
intense β1-receptor activity. 
 High caffeine doses induce adenosine antagonism and 
phosphodiesterases inhibition, interacting with the sympathetic 
nervous system and inducing β1-receptor activation. This 
results in positive inotropic and chronotropic effects, 
accountable for an augmented heart rate and conductivity 
[63]. In fact, higher concentrations of caffeine increase 
intracellular cAMP and cyclic guanosine monophosphate 
(cGMP) by a nonspecific phosphodiesterases inhibition, 
which affects cardiac contractility secondary to calcium 
release. The latter mechanism may increase the susceptibility 
for arrhythmias. Other caffeine’s mechanisms of action with 
indirect effects on the cardiovascular system have been 
reported, such as the stimulation of the sodium-potassium-
ATPase, which is an integral membrane protein responsible 
for a decrease in the plasma levels of potassium and the ion’s 
transfer from the circulation to intracellular compartments, 
rendering the membrane potential more negative. This 
determines an increased risk of ventricular arrhythmias [64]. 
According to the aforementioned mechanisms, arrhythmic 
episodes have been hypothesized to be responsible for death 
in cases of lethal intoxication. Caffeine, especially at high 
doses, leads to palpitations and arrhythmias, such as atrial 
fibrillation and supraventricular and ventricular ectopic beats 
(the latter also known as premature ventricular contractions, 
PVCs) [65]. It must be underlined that the positive inotropic 
effects of caffeine are reinforced by the positive chronotropic 
effects of guarana, a substance that is frequently added  
to energy drinks and contains caffeine, theobromine, and 
theophylline [66]. Berger et al. [67] reported ventricular 
fibrillation after overconsumption of a caffeinated energy 
drink in a 28-year-old healthy young man who was hospitalized 
and subsequently discharged after six days in healthy 
conditions. 
 Caffeine’s pro-arrhythmic effects at high doses are 
supported by animal studies [65, 68], which have been 
performed with higher doses of caffeine and evaluation  
by invasive techniques. Numerous physiological and 
epidemiological human studies have investigated the link 
between caffeine and both atrial and ventricular arrhythmias 
[69], but their results are not always in agreement.  
 The first human studies were carried out using invasive 
electrophysiology. Gould et al. [70] and Dobmeyer et al. 
[71] found a refractory period shortening of the atrio-
ventricular node and of the right atrium and ventricle after 
coffee intake: both effects were attributed to catecholamine 
release. Opposite results were found in the left atrium, whose 
refractory period paradoxically increased with caffeine 
intake.  
 As regards the effects of caffeine on the human 
electrocardiogram [69] after the intake of moderate amounts 
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of caffeine [72] or high-caffeine energy drinks [73], it was 
noticed that caffeine does not acutely induce any statistically 
and clinically significant changes in P-wave indices, i.e., PR 
interval, QRS duration, corrected QT interval (QTc), and RR 
interval [74]. Donnerstein et al. [75] observed a modest, but 
statistically significant prolongation of approximately 1 ms 
of signal-averaged QRS complexes in 12 individuals given a 
5 mg/kg body weight dose of caffeine vs. placebo.  
 In addition, studies of individuals performed with 
continuous electrocardiographic monitoring suggested that 
caffeine has a limited effect on the circuits underlying 
ventricular arrhythmias [69, 76, 77]. Therefore, despite 
increases in adrenaline levels, caffeine appears to have no 
proarrhythmic effect even in patients with clinical ventricular 
arrhythmias; caffeine showed no capacity of modifying the 
inducibility or severity of arrhythmias in patients with 
malignant ventricular arrhythmias [77] and did not induce an 
increase of cardiac ectopy, neither atrial nor ventricular, in 
patients with a high prevalence of baseline ectopy [69]. 
Furthermore, in high-risk patients with recent myocardial 
infarction no increase in the frequency or severity of PVCs 
or arrhythmias was found [69]. It is interesting to note that 
although adrenaline concentration increases with caffeine 
ingestion, the degree of the release is six times lower than 
the boost noted during exercise [78].  
 Larger-scale epidemiological studies found no increased 
risk of development of atrial arrhythmias after caffeine 
intake in healthy subjects [69]. A recent meta-analysis [79] 
suggested that it is unlikely that the chronic consumption  
of caffeine causes or contributes to atrial fibrillation. It was 
also demonstrated that in habitual caffeine consumers, 
caffeine’s adrenergic effects were greatly attenuated and 
acute proarrhythmic effect was somewhat reduced [80]. 
Furthermore, as atrial fibrosis is an important substrate for 
atrial fibrillation and caffeine has antifibrotic properties [81-
84], this finding might encourage the search for effective 
antifibrosis agents or the use of caffeine to prevent atrial 
fibrillation. 
 Prineas et al. [69] found that nine cups of coffee were 
associated with twice the risk of PVCs after adjusting for 
other risk factors. The same authors found a very significant 
association between heavy coffee intake (10 cups per day) 
and increased risk of sudden cardiac death in 117 patients 
with a history of coronary artery disease who suffered from 
sudden cardiac arrest vs. controls with coronary artery 
disease (odds ratio=55.7) [69]. However, a possible 
limitation may be represented by the fact that only two of the 
controls drank more than 10 cups of coffee per day  
 Some researchers have conjectured that caffeine is a 
vasoconstrictive substance [80, 85, 86]. In vitro studies have 
found that the concentration of intracellular calcium in 
vascular smooth muscle is modified by caffeine and this 
phenomenon could directly determine variations of coronary 
artery tone [67]. Caffeine has been shown to elevate blood 
pressure in both normotensive and hypertensive prone men, 
partly by inhibiting adenosine action, leading to elevated 
noradrenalin release and vasoconstriction [87, 88]. A number 
of studies have demonstrated that acute caffeine ingestion 
increases blood pressure and catecholamine levels and 
decreases heart rate [74, 89]. A study of caffeine’s ability to 
interfere with pharmacologic cardiac stress testing, showed 
in vivo increases in coronary vascular resistance and ascribed 
them to the antagonism of A2 receptors or to the induction of 
an α2-adrenoreceptor-mediated vasoconstriction consequent 
to the increase in catecholamine release [90]. It is well known 
that adenosine causes vasodilation, thus, the antagonization 
of adenosine receptors may induce vasoconstriction.  
 By contrast, caffeine also augments endothelium-
dependent vasodilation by agonist stimulation of endogenous 
nitric oxide production in young, healthy individuals. A 
double-blind, randomized study [55] showed that caffeine 
ingestion produced an increase in systolic and diastolic blood 
pressures in the brachial artery, in agreement with previous 
studies that highlighted how acute caffeine ingestion elevated 
peripheral blood pressure [80, 86, 91] and augmented the 
forearm blood flow response to acetylcholine, an endothelium-
dependent vasodilator. It has been reported that caffeine 
stimulates nitric oxide synthesis in the endothelium via the 
release of calcium from the endoplasmic reticulum by activating 
the ryanodine-sensitive calcium channel and inhibiting the 
breakdown of cGMP in the aorta: this results in the caffeine-
induced increase of endothelium-dependent vasodilation 
[92]. A balance between the vasodilatory effect of caffeine as 
an endothelium-dependent vasodilator and its vasoconstrictive 
effect as an adenosine receptor antagonist may control 
vascular function. High caffeine concentrations may cause 
marked hypotension secondary to vasodilation and, thus, 
ventricular fibrillation, which could be a possible mechanism 
of cardiovascular collapse [93]. 
 Blood pressure changes induced by acute caffeine 
ingestion need to be further investigated. Karatzis et al. [94] 
observed, after the acute administration of caffeine, an 
increase of central blood pressure, but not of peripheral 
systolic blood pressure. Therefore, there seems to be a 
relevant acute effect of caffeine ingestion on central 
hemodynamics, but not on peripheral pressure.  
 Several factors, such as age, exercise-induced stress, and 
hypertension, have been reported to influence blood pressure 
changes induced by caffeine [86]. Forman et al. [95] 
suggested that high doses of caffeine and low estrogen levels 
may act in a synergistic way to induce coronary arteries 
vasoconstriction.  
 These observations highlight the importance of keeping 
fairly constant any confounding factor when carrying out 
experimental studies, in order to assess correctly the blood 
pressure changes during caffeine administration. 
 Similarly, case-control and prospective studies have 
shown differing result with regard to the risk of myocardial 
infarction among patient with high coffee intake. A potential 
role of caffeine in promoting the development on cardiac 
ischemia has been suggested, taking into account the higher 
oxygen demand deriving from increased cardiac work levels 
and, in addition, caffeine’s direct effect on the coronary 
arteries [95]. There are case reports [67, 96] of coronary 
artery vasospasm induced by caffeine-containing energy drinks, 
but there is not enough evidence to support a relationship 
between caffeine and vasospasm. In vitro, caffeine has 
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physiological effects on the concentration of intracellular 
calcium in the vascular smooth muscle and could induce 
coronary vasospasm; in vivo, caffeine reduces myocardial 
blood flow during exercise [97]. Benjo et al. [98] reported 
left main coronary artery acute thrombosis related to 
caffeinated energy drinks intake, but it is difficult to single 
out which compound – e.g., caffeine, glucoronolactone, 
taurine, or vitamins – is responsible for the effect on platelet 
aggregation and endothelial function. Caffeine has not been 
shown to affect platelet function by itself, and no studies of 
the other compounds are available [99]. 
 Finally, extensive studies performed in cohorts of both 
healthy and diabetic subjects have demonstrated minimal or 
no effect of caffeine on coronary artery disease, myocardial 
infarction, and stroke [100-102]. A study of patients with 
coronary artery disease, in which exercise stress tests were 
carried out, showed that caffeine at a dose of 250 mg had no 
effect on exercise duration, time to onset of angina, and time 
to onset of ST-segment depression, although peak blood 
pressure increased by 7 mmHg [103]. Another study 
speculated that the regular intake of caffeinated beverages 
could provide protection against the risk of cardiovascular 
disease mortality in nonhypertensive elderly patient [104].  
Effects on the Central Nervous System 
 Caffeine, besides influencing cognitive performance, 
increases the perception of alertness and wakefulness [105, 
106] and sometimes induces anxiety, especially at high doses 
[107-109]. Furthermore, antagonism of A1 and A2 receptors 
can cause seizures and cerebral vasoconstriction. 
 Even if caffeine seems to prevent or restore memory 
losses or other disorders due to disturbances in brain 
homeostasis [7], its cognitive enhancement properties are 
still under discussion [8, 110]. A wide range of studies in 
humans suggest that the cognitive benefits of caffeine are 
associated with relief from withdrawal symptoms, rather 
than with improvement in cognitive functions [9, 111, 112]. 
In 2001, the Institute of Medicine Food and Nutrition Board 
Committee on Military Nutrition Research reported that the 
ingestion of caffeine at a dose of 150 mg enhances cognitive 
performance for at least 10 hours [113]. 
 While the benefits of caffeine on cognitive functions 
remain under debate, the anxiety-inducing effects are well 
documented in both animals and humans [114-117]. Caffeine 
actions are dose-related and divided into two broad 
categories: at lower concentrations, caffeine stimulates the 
locomotor activity [118], at higher concentrations it induces 
an anxiogenic-like effect [117, 119, 120]. 
 Caffeine is studied in relation to the possible treatment of 
neurodegenerative diseases, such as Alzheimer’s and 
Parkinson’s diseases. In epidemiological reports, caffeine 
consumption was associated with a significantly lower  
risk of developing them [4, 11, 12, 120-122, 124]. Recent 
experimental evidence suggests that the primary target of the 
neuroprotective effects of caffeine [124, 125] is either the 
activation or the inhibition of the A1 and A2A adenosine 
receptor subtypes [126, 127] (Table 1; findings not discussed 
in this review). The use of adenosine receptor antagonists, 
such as caffeine, has shown its usefulness not only in the 
treatment, but also in the protection against the aforementioned 
diseases [128-131]. Experimental evidence supports the use 
of caffeine and other adenosine receptor antagonists, as well as 
adenosine receptor agonists, in the reduction of hyperalgesia, 
excitotoxicity, inflammatory response, dyskinesia, akinesia, 
sensory and motor deficits, and neuronal cell death related to 
the pathophysiology of the discussed neurodegenerative 
diseases [132, 133]. 
 Caffeine has several effects on pain. It has been 
employed as a coadjuvant in the treatment of pain for many 
years. However, the analgesic effects of caffeine have not 
been properly studied until 1984, when it was demonstrated 
Table 1. Findings of caffeine effects on main neurodegenerative diseases. 
Known Effects on Neurodegenerative Diseases Drug Type (Adenosine 
Receptor Subtype) 
Parkinson’s Disease Alzheimer’s Disease (AD) 
Improves motor activity [7, 134]. Prevents the accumulation of amyloid-β- peptide (Aβ) in and 
around cerebral blood vessels [135]. 
Down-regulates neuroinflammatory responses and 
nitric oxide (NO) production [136, 137]. 
Reverses cognitive impairment and decreases brain Aβ levels in 
AD mice [138]. 
Reduces both motor and nonmotor early onset 
symptoms [139]. 
Consumption of 3-5 cups/day of coffee at midlife is associated 
with a decreased risk of dementia/AD by about 65% in later life 
[129]. 
Prevents the loss of nigral dopaminergic neurons [140]. Protects against oxidative stress and AD-like pathology in rabbit 
hippocampus [141]. 
Increases mitochondrial function and blocks melatonin signaling to 
mitochondria [143]. 
Caffeine (adenosine 
receptor antagonist) 
Protects against disruptions of the blood-brain barrier in 
animal models [142]. 
Men in the highest quartile of caffeine intake are less likely than 
men in the lowest quartile to have any lesion type [144]. 
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that the use of the compound as an additive reduced  
the amount of acetaminophen necessary to obtain the  
same effect by about 40% [145]. In vitro and in vivo 
pharmacological studies provided evidence that caffeine 
could have an antinociceptive action through the blockade of 
adenosine receptors and the inhibition of cyclooxygenase-2 
enzyme synthesis. Nevertheless, these actions occur only 
occasionally: it is hypothesized that the doses of analgesics 
and caffeine used nowadays can influence the analgesic 
adjuvant effect of caffeine, but doses that are either too low 
or too high determine no analgesic enhancement. 
 A number of headache studies have reported that  
acute caffeine ingestion produces an intrinsic analgesic effect 
[146, 147]. Caffeine in high doses, of about 300-500 mg, 
soothed post-dural puncture headaches [148], but repeated 
administration of lower doses did not produce such an effect 
[149]. The vasoconstrictor action of caffeine, secondary to 
adenosine receptor antagonism, is implicated in headache 
relief [150]. After chronic caffeine ingestion, cessation of 
intake was shown to cause a withdrawal syndrome 
dominated by headache and fatigue; symptoms manifested 
themselves after 12-24 hours, reached a peak at 24-48 hours, 
and persisted for about one week [151]. Headaches were 
originally documented as part of withdrawal symptoms after 
high intake levels that went beyond 600 mg/day, but they 
occurred even after moderate intake levels, equal to 100 
mg/day [152]. 
Tolerance and Safety Doses 
 The extent of the development of tolerance towards 
caffeine’s effects is unclear [153, 154]. The uncertainty 
regarding this issue may be partly due to methodological 
limitations. The majority of studies compare caffeine “naïve” 
individuals to habitual caffeine users, or habitual users 
before and after caffeine abstinence. As 80% of the 
population report regular use of caffeine, nonusers are much 
selected, atypical subpopulation. Response differences may 
merely reflect genetic differences between nonusers and 
habitual users, or an atypical response to caffeine that might 
have led to nonusers’ caffeine avoidance. Furthermore, very 
few studies compare individuals subjected to repeated 
caffeine administration vs. controls taking placebo. The 
recent literature suggests that the development of caffeine 
tolerance is partial and may differ with regard to caffeine’s 
central vs. peripheral effects. 
 As for central effects, a study assessed human brain 
metabolic response to caffeine using rapid proton echo-
planar spectroscopic imaging in regular caffeine users [154]. 
In the hour following caffeine intake (10 mg/kg body 
weight) brain lactate was increased in caffeine “naïve” 
individuals compared to regular caffeine users. In the regular 
caffeine users, after a 4-8 weeks abstinence, caffeine 
reexposure incremented brain lactate to a similar level to that 
of the caffeine “naïve” individuals. Thus, most of the studies 
suggest either complete or partial tolerance to caffeine’s 
central effects.  
 The peripheral effects of caffeine and the possible 
development of tolerance towards them have been more 
extensively analyzed because of concerns regarding dietary 
caffeine intake and cardiovascular status [155]. A study 
employing the same caffeine administration methodology as 
the one of the above cited study, which regarded the central 
effects of caffeine, found that caffeine elevated peripheral 
blood pressure vs. placebo and the blood pressure response 
was not abolished after five days of caffeine doses of 600 
mg/day. The sympathetic nervous system has an important 
role in regulating blood pressure [156]. A study assessed 
sympathetic nerve activity and blood pressure in habitual and 
nonhabitual coffee drinkers [80]. In comparison with 
placebo, caffeine at a dose of 250 mg elevated blood 
pressure in nonhabitual drinkers, but not in habitual ones. In 
contrast, the activity of the sympathetic nervous system was 
similarly increased in both groups. Most importantly, plasma 
caffeine concentrations did not differ between the two 
groups. Therefore, tolerance to the peripheral effects of 
caffeine may be variable, depending on the response system 
assessed, but it appears to be less consistent than tolerance to 
its central effects. 
Caffeine-containing Products 
 The most common dietary source of caffeine is coffee, 
but cocoa beverages, soft drinks, energy drinks, medications, 
and specialized sports foods and supplements also contribute 
to regular intake. Since the introduction of Red Bull in 
Austria in 1987 and in the US in 1997, the energy drink 
market has enormously expanded. Countless brands can now 
be found, with caffeine content ranging from a modest 50 
mg to an alarming 500 mg per can or bottle. The regulation 
of energy drinks, including their labeling, permissible 
maximum caffeine levels, and health warnings, has been 
rather complex in most countries, with one of the most  
lax normative frameworks in the US. Because of the  
varying amounts of caffeine consumed in each country, it is 
difficult to set an international standard. This has resulted in 
aggressive marketing of energy drinks, targeted primarily at 
young individuals, for physical performance enhancing and 
psychostimulatory effects. Furthermore, several studies 
suggest that energy drinks may serve as a gateway to other 
forms of substance dependence. In the recent years, to limit 
this phenomenon, regulatory upper limits have been set for 
those beverages in which caffeine is not contained naturally, 
but added either from a natural or a synthetic source.  
 As already mentioned, caffeine consumption has been 
linked with a number of health issues. There are increasing 
reports of caffeine abuse, dependence, and withdrawal 
syndromes, and it seems likely that caffeine intoxication will 
also increase. In children and adolescents who are not 
habitual caffeine users, vulnerability to caffeine intoxication 
is significantly higher due to the absence of pharmacological 
tolerance. Genetic factors may also contribute to an 
individual’s vulnerability to caffeine-related disorders.  
 In sports, caffeine use is very common. A moderate dose 
of caffeine (3-5mg/kg body weight) taken an hour before a 
hard training or competition, has been found to significantly 
increase performance as compared to placebo, with the 
athletes affected by minimal side effects. Prior to 2004, 
caffeine was included in the World Anti-Doping Agency 
(WADA) Prohibited List of substances and methods, with a 
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legal urinary concentration limit of 12µg/ml; however, it was 
subsequently removed, allowing athletes who compete in 
sports compliant with the WADA code to consume caffeine 
within their usual diets or for specific purposes of performance. 
This revision was based on the acknowledgment that 
caffeine enhances performance at doses that are impossible 
to differentiate from daily caffeine use and that the practice 
of monitoring caffeine use via urinary concentration is not 
completely reliable. However, the WADA continues to 
measure caffeine levels through urinary concentration testing 
within its Monitoring Program, in order to investigate 
patterns of misuse of substances in sport. Differently from 
the WADA, the National Collegiate Athletic Association 
(NCAA), a nonprofit association that regulates the athletes 
of 1,281 institutions and associations, and organizes the 
athletic programs of many colleges and universities in the 
US and Canada, has a urinary concentration limit of 
15µg/ml; thus, athletes in the NCAA must take into account 
that caffeine is still on the list of controlled substances. 
 The amount of caffeine contained in a cup of coffee can 
vary greatly, depending on its origin or the composition of 
the blend, the brewing method, and the strength of the brew. 
Instant (also known as soluble) coffee generally contains less 
caffeine than roast and ground coffee, but is usually 
consumed in greater volumes. Robusta coffees contain about 
twice as much caffeine than arabicas. A cup is usually 
assumed to contain 180 ml of coffee, but an espresso may 
contain as little as 40 ml [157]. 
 Decaffeinated coffee, regardless of the method of 
decaffeination, must contain less than 0.1% caffeine by dry 
weight to comply with regulations. This corresponds to 
about 3-5 mg of caffeine in a cup of decaffeinated coffee.  
 Tea contains more caffeine than coffee by dry  
weight, but less weight is used, in general, to brew a cup  
of tea. Both the type of tea and the infusing time can affect 
the amount of caffeine. The caffeine content of a cup of tea 
is usually less than 60 mg, but a strong cup of tea may 
contain more caffeine than a weak cup of regular coffee 
(Table 2).  
 Cocoa and chocolate drinks contribute to the diet with 4-
5 mg of caffeine per cup, dark chocolate and cooking 
chocolate with 0.7-0.9 mg per gram.  
 Numerous soft drinks, including colas and peppers, 
contain caffeine, which, as well as being present in cola nuts, 
is often added as a flavoring agent. About 180 ml of a soft 
drink contain 30-70 mg of caffeine. The major brands of cola 
sold in Europe contain about 120 mg of caffeine per liter 
(Table 2). 
 Caffeine is present in many prescription and nonprescription 
(i.e., over-the-counter) medications, including some taken 
for headache, pain relief, cold, appetite control, staying 
awake, asthma, and fluid retention. The caffeine content of 
drugs varies from 16 mg to 200 mg per tablet (Table 2). 
 Energy drinks contain high concentrations of caffeine, as 
well as other performance-enhancing substances, such as 
guarana, taurine, and B vitamins. They claim to provide its 
consumers with extra energy (Table 2). 
 Caffeine consumption has been classified as follows: 
- low caffeine users: <200 mg/day 
- moderate caffeine users: 200-400 mg/day 
- high caffeine users: >400 mg/day 
Caffeine use, Abuse, and Dependence 
 Reissig et al. [159] have described several negative 
effects of excessive caffeine consumption. Throughout their 
lives, individuals can consume high quantities of caffeine 
only for some periods of time, but more often on a regular 
basis. Moreover, some individuals go on to abuse caffeine to 
enhance their concentration and memory or to improve their 
physical performance, and in some cases develop a 
dependence syndrome. Caffeine use becomes “abuse” when 
an uncontrolled urge to consume caffeine arises, even if it is 
detrimental for health; it becomes “dependence” when 
tolerance and abstinence mechanisms occur and there are 
some habits of chronic use that render caffeine even more 
harmful. In caffeine dependence, individuals start to 
consume extremely high doses, ignoring all safety issues; 
they take a combination of two or more different sources of 
caffeine, for example, coffee and energy drinks, although the 
combination is not proven to have any added desirable 
effects; they consume caffeine almost continuously for years, 
reaching an excessive cumulative duration of use.  
 The effects of caffeine dependence are still under 
investigation. One issue in studying caffeine dependence has 
been the uncertainty regarding the products that contain 
caffeine and their respective concentration of caffeine,  
thus the existing studies, mainly observational, have often 
found difficulties in verifying the exact nature or amounts 
taken. Moreover, many individuals who consume caffeine 
simultaneously consume other substances, such as nicotine 
or alcohol, which may have overlapping effects. Another 
issue has been the application of appropriate criteria. A 
“substance dependence disorder” was coded by the 
American Psychiatric Association (APA) in 1989 [160]. 
Over the years, the existing literature has applied DSM-IV-
TR [161] or previous criteria to assess dependence among 
populations of users. A problem that has arisen is that the 
standard DSM-IV-TR substance dependence criteria are 
difficult to apply to some compounds, such as caffeine,  
since they were designed largely to apply to intoxicating 
drugs. For example, even if caffeine causes the classic 
withdrawal syndrome, mediated by neuroendocrine and 
cortical neurotransmitter systems, it is a cumulatively acting 
substance that produces little or no acute intoxication, unless 
taken in large doses. Hence it does not usually compromise 
daily functioning in the manner of intoxicating drugs. In an 
attempt to address this problem, the DSM-5 [162] suggested 
the code “substance use disorder”, where the specific 
substance has to be indicated, i.e., caffeine, nicotine, alcohol, 
cannabis, hallucinogen (phencyclidine and others), inhalant, 
opioid, sedative, hypnotic, anxiolytic, or stimulant categories. 
Substance use disorder in DSM-5 combines the DSM-IV-TR 
categories of substance abuse and substance dependence into 
a single disorder measured on a continuum from mild to 
severe. Each specific substance is addressed as a separate 
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Table 2. Average caffeine content in foods, beverages, and medications (adapted from Cherniske, 1998 [158]). 
Servings per day Item Total Caffeine (in mg) 
Drip brewed 100 mg per 180 ml 
Percolated 120 mg per 180 ml 
Instant 90 mg. per 180 ml 
Brewed decaffeinated 5 mg per 180 ml 
Coffee (180 ml cup) 
Instant decaffeinated 3 mg per 180 ml 
Green 35 mg per 180 ml 
Black 70 mg per 180 ml 
Tea (180 ml cup) 
Canned ice tea 35 mg per 360 oz can 
Cocoa Cocoa beverages 13 mg per 180 ml 
Milk chocolate 6 mg per 30 ml 
Baking chocolate 35 mg per 30 ml 
Chocolate 
Small candy bar 25 mg per bar 
Leading colas (regular and diet) 45 mg 
Dr. Pepper 40 mg 
Mello Yello 53 mg 
Mountain Dew 54 mg 
Mr. Pibb 41 mg 
OK Soda 40 mg 
Soft drinks (360 ml can) 
Jolt Cola 72 mg 
Anacin 32 mg 
Dristan (i.e., acetylsalicylic acid+caffeine) 16 mg 
Dexatrim (i.e., phenylpropanolamine+caffeine) 16 mg 
Excedrin (i.e., acetaminophen+acetylsalicylic acid+caffeine) 200 mg 
Midol (i.e., acetaminophen+pyrilamine maleate+caffeine) 32 mg 
Nodoz (i.e., caffeine) 100 mg 
Vivarin (i.e., caffeine) 200 mg 
Medications (per tablet) 
Vanquish (i.e., acetaminophen+acetylsalicylic acid+caffeine) 33 mg 
28 Energy Drink 80 mg 
6 Hour Power 125 mg 
BANG Energy Drink 357 mg 
Biggby Iced Coffee 192 mg 
Caffeine Energy Drink 140 mg 
Chameleon Cold Brew Coffee 2160 mg 
Cocaine Energy Drink 280 mg 
Diablo Energy Drink 95 mg 
Energy drinks 
Guayaki Empower Mint 140 mg 
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Table 2. contd…. 
Servings per day Item Total Caffeine (in mg) 
Hardcore Energize Bullet 300 mg 
Java Monster 188 mg 
Liquid Lightning 200 mg 
Monster Energy Drink 160 mg 
Neurofuel Energy Drink 128 mg 
Octane Energy Drink 225 mg 
Potencia Energy Drink 250 mg 
Rage Inferno 375 mg 
Red Bull 80 mg 
Speed Energy Drink 186 mg 
Starbucks Tall Coffee 260 mg 
Ubermonster Energy Brew 160 mg 
Venom Black Mamba 160 mg 
Energy drinks 
Zun Energy Drink 100 mg 
 
disorder, but nearly all substances are diagnosed based on 
the same overarching criteria. These criteria have not only 
been combined, but strengthened. Whereas in the past a 
diagnosis of substance abuse required only one symptom, 
substance use disorder in the DSM-5 requires at least two 
symptoms from a list of eleven. Substance craving was 
added to the list and problems with law enforcement were 
eliminated because of cultural considerations that made the 
criteria difficult to apply internationally. The revised substance 
use disorder, a single diagnosis, better matches the symptoms 
that individuals experience. Furthermore, in the past the 
diagnosis of dependence caused much confusion. Most people 
linked dependence with addiction, when in fact dependence 
can be a normal body response to a substance. DSM-5 
diagnostic criteria for dependence are listed in Table 3. 
 The disorder can occur in a broad range of severity, 
basing on the number of symptom criteria endorsed: mild, if 
2 to 3 symptoms are present, moderate if 4 to 5 symptoms 
are present, and severe if 6 or more symptoms are present. 
 As said before, it can be noted that the DSM-5 includes 
the craving criteria. Craving is a key element in the genesis 
of substance addiction and relapse that often individuals with 
abuse or dependence encounter. Initially, the term was used 
to describe, in opiate addicts, a strong and irresistible urge 
arising during withdrawal. Subsequently, it has come to 
indicate a desire to make use of any psychotropic substance 
in any situation. The WHO [163] describes craving as an 
“intense and compulsive desire to experience the effects of a 
psychoactive substance used in the past”, which, in simpler 
terms, indicates a strong urge to use the substance. Once 
considered a manifestation of the withdrawal syndrome, 
craving appears to be essentially the result of a stimulus 
evoking the substance, but sometimes its onset is not 
apparently linked with any stimulus; it tends to diminish 
with time, but it can appear even after years of abstinence. 
This urge can become compelling and may increase in the 
presence of internal and external stimuli (i.e., “triggering 
events”) and the perception of the availability of the substance. 
It is characterized by a behavior aimed at obtaining the 
substance and by intrusive thoughts that focus on the 
substance, such as intrusive thoughts about caffeine. In the 
field of psychiatry two types of craving are distinguished 
[164]: 1) physical craving that occurs in substance addicts or 
alcoholics who stop taking drugs or drinking after a long 
period of excessive consumption; this type of craving is 
mostly associated with physical symptoms of the withdrawal 
type, such as increased heart rate, sweating, nausea, agitation, 
tremors, etc.; 2) psychological craving that occurs during 
abstinence and often leads to relapse. It is related to the 
activation of the reward system, located in the brain in the 
medial forebrain bundle, which includes the dopaminergic 
meso-cortico-limbic pathway. 
 Finally, individuals – both adults and adolescents – who 
consume high doses of caffeine frequently report psychiatric 
symptoms and disorders, mainly anxiety and mood 
disorders, but also behavioral alterations. Some disorders are 
typically linked to recreational and professional athletes who 
consume caffeine to face fatigue and intense workouts. An 
example is muscle dysmorphia. This disorder, also known as 
reverse anorexia or bigorexia or Adonis complex, is a 
subtype of body dysmorphic disorder generally affecting 
men, with its onset in adolescence or early adulthood, 
characterized by obsessiveness and compulsivity directed 
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toward achieving a lean and muscular physique, even at the 
expense of health. This raises the issue of whether caffeine 
use causes these disorders in athletes, by inducing 
neuroadaptive changes within the reward neural circuit and 
affecting mechanisms of resilience to stress, or, vice versa, 
athletes with pre-morbid abnormal personalities or a history 
of psychiatric disorders are attracted to caffeine use, 
encouraged by an extrinsic motivation for exercise focused 
on appearance and weight control. 
Caffeine Toxicity 
 Caffeine intoxication is a recognized clinical syndrome 
included in the DSM-5 [162] and the World Health 
Organization’s International Classification of Diseases (ICD-
10) [165]. Caffeine toxicity is defined by specific symptoms 
that arise as a direct consequence of caffeine consumption. 
 Common features of caffeine intoxication, also known as 
“caffeinism” (i.e., a state of chronic toxicity from excessive 
caffeine consumption), include anxiety, agitation, 
restlessness, insomnia, gastrointestinal disturbances, tremors, 
tachycardia, psychomotor agitation, and, in some cases, 
death (see Table 4). Symptoms of caffeine intoxication can 
mimic those of anxiety and other affective disorders [166]. 
Energy drink consumption may increase the risk of caffeine 
overdose in caffeine abstainers, as well as habitual caffeine 
users. 
 Caffeine intake at very high doses, exceeding 500-600 
mg, which are equivalent to 4-7 cups per day, can cause 
anxiety, tremor, and tachycardia. This mechanism of action 
requires higher concentrations of caffeine, unlikely to be 
reached with the common amount of caffeine contained in 
dietary sources. The acute toxic level of caffeine is not well 
established, but for adults it is approximately 10 g/day, 
which is comparable to a consumption of approximately 100 
cups of coffee [167]. 
 Generally, life-threatening caffeine overdoses entail the 
ingestion of caffeine-containing medications, rather than 
caffeinated foods or beverages [168], and have been 
associated with blood concentrations in excess of 80 mg/l 
[169].  
 In the majority of lethal cases, caffeine was introduced as 
a dietary supplement or with other substances, such as 
stimulant drugs and alcohol.  
 Only in one lethal case, described by Chaturvedi et al. 
[174], the concentration of caffeine was below the fatal 
levels and above the toxic levels: this was a case of multi-
chemical death involving caffeine and nicotine. It appears 
that the interaction between the two substances in the body 
tissues played a role, due to the rapid onset of the toxicity 
leading to an early death [165, 186-189].  
DISCUSSION 
 In recent years caffeine use has increased, especially 
among young people, due to the wide diffusion of 
caffeinated beverages advertised as energy drinks. Despite 
the wide diffusion of caffeine in the form of drinks, foods, 
and medications, death from acute intoxication is relatively 
rare and is mostly caused by voluntary or involuntary 
ingestion of tablets containing pure caffeine in high 
concentrations. In fact, although variable amounts of 
Table 3. DSM-5 diagnostic criteria for dependence. At least two of the following criteria must be met over a 12-month period. 
Criteria 
The substance is often taken in larger amounts or over a longer period than was intended 
There is a persistent desire or unsuccessful efforts to cut down or control use of the substance 
A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects 
Craving, or a strong desire or urge to use the substance 
Recurrent use of the substance resulting in a failure to fulfill major role obligations at work, school, or home 
Continued use of the substance despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of its use 
Important social, occupational, or recreational activities are given up or reduced because of use of the substance 
Recurrent use of the substance in situations in which it is physically hazardous 
Use of the substance is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused 
or exacerbated by the substance 
Tolerance, as defined by either of the following: 
a) a need for markedly increased amounts of the substance to achieve intoxication or the desired effect 
b) a markedly diminished effect with continued use of the same amount of the substance 
Withdrawal, as manifested by either of the following: 
a) the characteristic withdrawal syndrome for the substance 
b) the substance (or a closely related substance) is taken to relieve or avoid withdrawal symptoms 
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Table 4. Lethal cases of caffeine intoxication. 
Author (Year) Caffeine Blood Level (mg/L) Age Manner of Death Route of Administration (Source) 
158.5 5-year-old Accidental Oral (pills) 
1040 15-month-old Accidental Oral (pills) 
Dimaio et al. (1974) [170] 
79 45-year-old Accidental Oral (pills) 
Turner et al. (1977) [171] 106 34-year-old Uncertain Oral (pills) 
McGee (1980) [172] 181 19-year-old Accidental Oral (pills) 
Bryant (1981) [173] 113.5 42-year-old Suicide Oral (pills) 
Chaturvedi et al. (1983) [174] 62 21-year-old Suicide Oral (pills) 
129.9 19-year-old Suicide Oral (pills) 
147 21-year-old Suicide Oral (pills) 
343.9 21-year-old Suicide Oral (pills) 
184.1 23-year-old Accidental Oral (pills) 
Garriott et al. (1985) [175] 
251 21-year-old Suicide Oral (pills) 
Winek et al. (1985) [176] 240 21-year-old Suicide Oral (pills) 
Morrow (1987) [177] 117.3 14-month-old Child abuse Oral (pills) 
Mrvos et al. (1989) [178] 1560 22-year-old Accidental Oral (pills) 
220 19-year-old Accidental Oral (pills) Riesselmann et al. (1999) [179] 
190 81-year-old Suicide Oral (pills) 
173 54-year-old Uncertain Oral (pills) 
210 21-year-old Suicide Oral (pills) 
153 31-year-old Suicide Oral (pills) 
Holmgren et al. (2004) [180] 
200 47-year-old Uncertain Oral (pills) 
192 39-year-old Accidental Intravenous Kerrigan et al. (2005) [181] 
567 29-year-old Accidental Oral (pills) 
90 43-year-old Uncertain Not reported 
105 53-year-old Suicide Not reported 
170 47-year-old Uncertain Not reported 
86 26-year-old Uncertain Not reported 
210 25-year-old Suicide Not reported 
230 40-year-old Uncertain Not reported 
210 21-year-old Suicide Not reported 
153 31-year-old Suicide Not reported 
173 54-year-old Uncertain Not reported 
200 47-year-old Uncertain Not reported 
180 18-year-old Suicide Not reported 
166 20-year-old Suicide Not reported 
Thelander et al. (2010) [182] 
140 72-year-old Suicide Not reported 
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Table 4. contd…. 
Author (Year) Caffeine Blood Level (mg/L) Age Manner of Death Route of Administration (Source) 
80 24-year-old Suicide Not reported 
160 46-year-old Suicide Not reported 
113 73-year-old Uncertain Not reported 
138 66-year-old Accidental Not reported 
190 84-year-old Suicide Not reported 
192 79-year-old Suicide Not reported 
Thelander et al. (2010) [182] 
310 33-year-old Suicide Not reported 
Jabbar et al. (2013) [183] 350  39-year-old Accidental Oral (pills) 
Jantos et al. (2013) [184] 141 25-year-old Suicide Oral (pills) 
Bonsignore et al. (2014) [185] 170 31-year-old Suicide Oral (pills) 
220 57-year-old Suicide Oral (pills) 
320 50-year-old Uncertain Oral (pills) 
90 39-year-old Uncertain Oral (pills) 
320 43-year-old Suicide Oral (pills) 
Banerjee et al. (2014) [93] 
74 44-year-old Uncertain Oral (pills) 
 
 
caffeine are contained in coffee, tea, and other drinks, it is 
difficult to reach lethal doses of caffeine exclusively through 
one of these products.  
 On the basis of the known mechanisms of action, 
caffeine can be considered as a psychostimulant, since its 
main effects are correlated to the interfering action on the 
neuroendocrine control systems.  
 Caffeine’s psychological effects are also responsible for 
its widespread use, as they can provide energy and improve 
cognitive skills; they are a direct result of the caffeine-
induced chemical activation of different neuronal pathways 
through alterations in neurotransmitters’ release. These effects 
can cause both psychological and physical dependence. It 
has been demonstrated that caffeine is able to induce an 
abstinence syndrome during withdrawal after prolonged use 
and can lead to addiction and tolerance mechanisms, which 
on the one hand may determine a reduction of the 
“dangerous” cardiovascular effects, but on the other hand 
may increase frequency and amounts of consumption.  
 The effects of caffeine use on the cardiovascular system 
taken into account to evaluate the risk of acute and chronic 
cardiovascular diseases are also the result of the direct and/or 
indirect actions of caffeine on the neuroendocrine control 
systems of vascular resistance, cardiac function, and 
electrolyte balance.  
 Although cases of lethal intoxication have been mainly 
associated with the occurrence of arrhythmic events induced 
by caffeine, human studies provided scarce evidence to 
support the substance’s ability to induce arrhythmias in 
healthy subjects and in subjects predisposed to such events. 
These findings, however, even if provided by studies differing 
in sample sizes and methods, should not be considered in 
disagreement with the findings of those studies reporting 
cases of lethal intoxication, as the former take into account 
caffeine doses below the ones considered toxic for humans.  
 Furthermore, it should be considered that the concepts of 
toxic and lethal doses in humans are relative, as doses below 
the toxic and/or lethal range may play a causal role in 
inducing intoxication or death. This could be due to: 
- interactions with other substances that have a synergistic 
effect when consumed with caffeine or are capable of 
increasing caffeine’s blood levels; 
- individuals’ pre-existing conditions or diseases that can 
potentiate caffeine’ mechanisms of action; 
- inter-individual differences, mostly genetically determined, 
that can affect caffeine metabolism in both directions 
(i.e., increase or reduction), contributing to a different 
individual “sensibility” to the substance’s effects. 
CONCLUSION 
 Ultimately, the dangers of caffeine are related to the  
wide diffusion of the substance, which results in an only 
partially conscious high consumption, due to the difficulty  
of ascertaining the actual amount of caffeine ingested daily 
and the inability to predict specific effects in relation to  
the triggering role that caffeine may have – even at doses 
considered to be “safe” – on underlying and not necessarily 
known cardiovascular conditions. 
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 Caffeine, like other psychoactive substances, can induce 
abuse and dependence. Furthermore, caffeine, like alcohol 
and tobacco, is legally used, but, unlike the last two, its sale 
in the form of high concentration drinks or tablets is not 
controlled or restricted. 
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